Skip to main content

Share story

AI

Scaling Karpathy's Autoresearch with GPU cluster

Scaling Karpathy's Autoresearch with GPU cluster Image: Primary
A team directed the coding agent Claude Code at Andrej Karpathy's autoresearch project and provided access to 16 GPUs on a Kubernetes cluster. The agent employed SkyPilot to launch and manage jobs across the infrastructure. It utilized a combination of H100 and H200 GPUs as they became available. Over eight hours the agent submitted about 910 experiments. Scaling model width emerged as more impactful than changes to any other single hyperparameter. The agent lowered val_bpb from 1.003 to 0.974 for a 2.87 percent improvement over the baseline. Parallel operation permitted the agent to run factorial grids of 10 to 13 experiments in each wave. This capability revealed interaction effects among parameters that sequential testing would miss. The agent learned to screen ideas on H100 GPUs and promote successful ones to H200 GPUs for validation. The session produced roughly 90 experiments per hour. Throughput increased by a factor of nine relative to single-GPU runs. About 700 experiments yielded valid results.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from SkyPilot Blog and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.